Trial activity in regenerative medicine on the rise

Cold chain logistics firm Cryoport says that R&D activity in regenerative medicine increased 8.6% in the second quarter of 2017, according to the firm’s research.

The company uses clinical trial data published by the US National Institutes of Health, logistics processes, statistical measurements of success and other data to track activity in the development and clinical trials of regenerative therapies in the United States.

Cryoport says there were 284 active trials in Phase I, 539 in Phase II and 76 in Phase III during this period.

During the second quarter of 2017, approximately $2.45 billion was invested in this sector, an 88% increase from the second quarter of 2016.